Investor profile
Invus
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Invus is an evergreen equity investment firm founded in 1985, backed by Artal, a European family group, with over $10 billion under management across private equity, public equity, and the Invus Opportunities strategy. The firm partners with entrepreneurs and their teams to transform industries, providing long-term capital with no predetermined exit timeline, acting as the sole or lead institutional investor in a small handful of new investments each year. Invus focuses on consumer, technology, and life sciences across the U.S., Europe, India, and Southeast Asia, with initial equity checks ranging from under $10 million to as high as $800 million, covering early-growth companies through turnarounds. Invus Opportunities, launched in 2007, manages over $2.5 billion focused on private technology businesses globally—including fintech, marketplace, healthcare, and AI/software—investing as lead or co-investor alongside other firms. Across all strategies, Invus emphasizes 100% equity structures (no debt loading), full incentive alignment with founders, and a continuous capital structure that allows it to support companies from early growth through and beyond IPO.
Notable quotes
“Financial success isn't the only goal – it's a byproduct of doing the right thing, meeting the needs of the market and driving seismic changes in an industry.”
“We keep it simple. We want to win when our partner companies, their founders and teams win. We don't see a wall between us. We advise on the tangibles and intangibles, act as their sounding board on the big and small questions and aren't afraid to be direct about what isn't going well to get on the right track.”
“Investments are typically a single bet in a given space and a commitment to our partners' success, rather than taking a portfolio approach to a given theme or space. Each new investment needs to have the potential to move the needle on the full portfolio.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| City Therapeutics | Series B | $100m | 2026-06-08 |
| Contraline | Series C | $93m | 2026-05-29 |
| AlphaSense | Series E | — | 2024-06-01 |
| Nubank | Series G | — | 2021-01-01 |
| Coupang | Series H | — | 2018-01-01 |
| Plaid | Series D | — | 2025-04-03 |
| Brex | Later Stage VC | — | 2025-08-15 |
| dbt Labs | Later Stage VC | — | 2025-09-01 |
| Weight Watchers (WW International) | Private Equity | $226m | 1999-01-01 |
| Parabilis Medicines | Series B | — | 2021-03-01 |
Frequent co-investors
Fit check
Is Invus a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit